Calidi Biotherapeutics Announces Partnership with GenScript ProBio for Distribution of its SuperNova-1 Technology

Calidi Biotherapeutics, Inc. announced its partnership with GenScript ProBio for assistance in the advertisement and distribution of Calidi’s proprietary technology platform: SuperNova-1 (SNV-1). The SNV-1 platform is composed of allogeneic, adipose-derived-MSC loaded with an oncolytic agent such as the vaccinia virus.